MDT
NYSEMedtronic plc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$90.67+15.10 (+19.98%)
2026-05-282026-08-31
News · 26 weeks84-29%
2026-03-082026-08-30
Mix4090d
- Insider18(45%)
- Other11(28%)
- SEC Filings5(13%)
- Analyst3(8%)
- Offering2(5%)
- Dividends1(3%)
Latest news
25 items- SECMedtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Medtronic plc (0001613103) (Filer)
- PRMedtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidanceStrength across the company's largest franchises, new growth platforms, and recent portfolio investments support the long-term growth trajectoryGALWAY, Ireland, Sept. 1, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2027 (FY27), which ended July 31, 2026.Key HighlightsRevenue of $9.8 billion, increased 13.7% as reported and 13.7% organic, roughly 200 basis points above guidance midpointGAAP diluted EPS of $1.14; non-GAAP diluted EPS of $1.45, ahead of guidanceRaising FY27 organic revenue growth guidance 50 basis points to 7.25% to 7.75%, and FY27 diluted non-GAAP EPS guidance to th
- PRMedtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted SurgeryPartnership expands Medtronic's robotic-assisted surgery portfolio to expand access globally and gives surgeons and health systems more choice and flexibility$700 million investment includes rights to distribute Cornerstone Robotics' Sentire™ surgical system in select markets outside the U.S.Sentire will be a strong complement to Medtronic's Hugo™ robotic-assisted surgery (RAS) system, creating a unique portfolio of robotic solutionsGALWAY, Ireland, Sept. 1, 2026 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, today announced a strategic partnership with Cornerstone Robotics, an innovative surgical robotics company committed to advancing minimally invasive surgery and im
- PRMedtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVRGALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease, today announced a strategic investment by Medtronic in Pi-Cardia Ltd. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through this strategic investment, supporting the next generation of innovation. Pi-Cardia's ShortCut™ device is t
- ANALYSTNeedham reiterated coverage on Medtronic with a new price targetNeedham reiterated coverage of Medtronic with a rating of Buy and set a new price target of $114.00 from $101.00 previously
- INSIDEREVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,084 units of Ordinary Shares, decreasing direct ownership by 0.92% to 116,336 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- PRMedtronic announces cash dividend for second quarter of fiscal year 2027GALWAY, Ireland, Aug. 20, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company's cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in June 2026. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 49 consecutive years. The dividend is payable on October 16, 2026, to shareholders of record at the close of business on September 25, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, h
- SECSEC Form DEFA14A filed by Medtronic plc.DEFA14A - Medtronic plc (0001613103) (Filer)
- SECSEC Form DEF 14A filed by Medtronic plc.DEF 14A - Medtronic plc (0001613103) (Filer)
- PROrchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesThe BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both the AVIM Therapy and Virtue SAB programs. NEW HOPE, Pa., Aug. 10, 20
- PRMedtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmiasSphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablationNew indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continueSphere VT U.S. pivotal trial enrollment underwayGALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVCs). The Sphere-9 catheter is the firs
- INSIDERChief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 212 units of Ordinary Shares and was granted 2,337 units of Ordinary Shares, increasing direct ownership by 14% to 16,998 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP & President, Neuroscience Thompson Kweli covered exercise/tax liability with 1,739 units of Ordinary Shares and was granted 6,923 units of Ordinary Shares, increasing direct ownership by 17% to 35,390 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERSVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 1,675 units of Ordinary Shares and was granted 5,769 units of Ordinary Shares, increasing direct ownership by 11% to 39,928 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP, GC and Secretary Quinn Michelle was granted 6,346 units of Ordinary Shares, increasing direct ownership by 31% to 26,721 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP & Chief Financial Officer Pieton Thierry was granted 11,537 units of Ordinary Shares, increasing direct ownership by 30% to 49,645 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP, Pres MedSurg and Americas Marinaro Michael was granted 57,107 units of Ordinary Shares and covered exercise/tax liability with 3,356 units of Ordinary Shares, increasing direct ownership by 84% to 117,420 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 3,074 units of Ordinary Shares and was granted 9,230 units of Ordinary Shares, increasing direct ownership by 16% to 43,669 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERChairman and CEO Martha Geoffrey was granted 41,533 units of Ordinary Shares and covered exercise/tax liability with 15,810 units of Ordinary Shares, increasing direct ownership by 9% to 327,866 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP, GC and Secretary Quinn Michelle covered exercise/tax liability with 2,069 units of Ordinary Shares, decreasing direct ownership by 9% to 20,375 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- ANALYSTMedtronic upgraded by UBS with a new price targetUBS upgraded Medtronic from Neutral to Buy and set a new price target of $100.00
- PRA new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026Advanced compute power, built on NVIDIA infrastructure, enables real-time decision support during the procedureFDA-cleared Instrument Exit Point (IEP), the first real-time AI application for robotic procedures from Medtronic, advances a precise, predictable, and personalized future for surgeryGALWAY, Ireland, July 21, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, is presenting an early look at its next-generation compute platform for the operating room. Touch Surgery™ Aide — an AI-native surgical computing platform that powers the Touch Surgery™ ecosystem — enables real-time artificial intelligence during procedures. Touch Surgery™ Aide will be shared a
- PRMedtronic to announce financial results for its first quarter of fiscal year 2027GALWAY, Ireland, July 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31, 2026.A news release containing summary financial information will be issued at 5:45 a.m. Central Time (CT) and will be available at https://news.medtronic.com.A video webcast to discuss results will begin at 6:45 a.m. CT and can be accessed at https://investorrelations.medtronic.com.Within 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at http
- PRMedtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute painAcquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹GALWAY, Ireland, July 16, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management. The acquisition is valued at $650 million, consisting of an upfront cash payment.Chronic pain affects nearly 50 million U.S. adults2, and for some, it can significantly impact their mobility, sleep q
- INSIDERSVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
MDT FAQ
6 questionsWhat does Medtronic plc. do?
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered...Where does MDT stock trade?
Medtronic plc. (MDT) is listed on NYSE.What sector and industry is MDT in?
Medtronic plc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about MDT?
Medtronic plc. has had 8 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-08-27.What companies are similar to MDT?
Notable peers in the same industry include MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation), TMDX (TransMedics Group Inc.). Compare MDT side-by-side with any of them on Quantisnow.How can I track MDT on Quantisnow?
Quantisnow aggregates Medtronic plc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDT to receive live email and push alerts on every new disclosure.